MedTrace Logo

High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program

NCT05782881 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16000

Last updated 2023-12-15

No results posted yet for this study

Summary

High Risk Population of Cardiovascular Disease in Hubei Province (Coronary Heart Disease With Diabetes) Screening and Intervention Program（CCDInT）is a randomized controlled study to verify that protocol treatment group is more effective than the conventional treatment group in reducing the incidence of composite cardiovascular disease (cardiovascular death, non fatal myocardial infarction, non fatal stroke, hospitalization for heart failure, and readmission for acute coronary syndrome) in patients with coronary heart disease and type 2 diabetes.

Conditions

Interventions

BEHAVIORAL

phone calls and encouraging patients' lifestyle change and medication adherence

Use some methods to strictly intervene blood glucose , blood pressure and blood lipids for protocol treatment group people.

DRUG

Statin

Treatment and management according to the guidelines

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Kai Huang, doctor · Union Hospital, Tongji Medical College of Huazhong University of science and technology

  • Yong Huo, doctor · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-15
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05782881 on ClinicalTrials.gov